Key statistics
As of last trade Aurinia Pharmaceuticals Inc (AUPH:NMQ) traded at 8.96, -8.06% below its 52-week high of 9.74, set on Dec 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.75 |
---|---|
High | 9.04 |
Low | 8.65 |
Bid | 8.95 |
Offer | 8.96 |
Previous close | 8.77 |
Average volume | 1.57m |
---|---|
Shares outstanding | 143.18m |
Free float | 132.93m |
P/E (TTM) | -- |
Market cap | 1.26bn USD |
EPS (TTM) | -0.1582 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 17:31 GMT.
More ▼
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
- Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
- Aurinia to Participate in Jefferies London Healthcare Conference
- Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
- Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
- Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
- Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
- Aurinia Announces Board Restructuring
More ▼